Quanterix Q2 net loss widens to $48.93 million; revenue rises 34% to $32.9 million

• Quanterix posted Q2 revenue of $32.9 million, up 34% year over year, as GAAP net loss widened to $48.93 million.
• GAAP gross margin slipped 2.4 percentage points to 38.5%, while non-GAAP adjusted EBITDA loss narrowed to $10 million from $13.7 million.
• Cash, cash equivalents, marketable securities, and restricted cash totaled $96.9 million; it recorded a $26.9 million GAAP goodwill impairment tied to Akoya.
• Outlook cut: 2026 revenue seen at $142 million-$148 million; cash-flow breakeven now expected in 2027 with about $80 million year-end cash.
• Management cited execution challenges and market softness; Anthem Blue Cross and Blue Shield began covering Lucent AD Complete qualifying blood-based biomarker testing from July 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202608100800BIZWIRE_USPR_____20260810_BW542022) on August 10, 2026, and is solely responsible for the information contained therein.